No Data
No Data
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Barinthus Bio Cuts 25% of Staff Amid Pipeline Shakeup
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $5
Barclays Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $3
Express News | Barinthus Biotherapeutics PLC : Barclays Cuts Target Price to $3 From $7
No Data